Lenalidomide as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Exploration of Biomarkers for Treatment Efficacy

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14270
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma

Cancer
Cancer ResearchOncology
2017English

Second-Line Treatment Options in Hepatocellular Carcinoma

Drugs in Context
Molecular MedicinePharmacology
2019English

Molecular Targeted Agents as Second-Line Treatment for Hepatocellular Carcinoma: A Meta-Analysis and Review

Oncotarget
Oncology
2017English

Triplet Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin as Second-Line Therapy for Advanced Urothelial Carcinoma

Modern Chemotherapy
2013English

Optimal First‐line Treatment for Advanced Thymic Carcinoma

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Economic Evaluation of Nivolumab as a Second-Line Treatment for Advanced Renal Cell Carcinoma From US and Chinese Perspectives

Cancer
Cancer ResearchOncology
2017English

Stereotactic Body Radiation Therapy as an Alternative Treatment for Small Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2013English

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Marine Drugs
Drug Discovery
2009English

Safety and Efficacy of 6-Thioguanine as a Second-Line Treatment for Autoimmune Hepatitis

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy